IPO - Profile

Summary

We are a leading provider of critical reagents that enable the discovery, development and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Our 3,000 active customers span the continuum of the life sciences market, including leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our company is built around proprietary development and manufacturing processes that are highly adaptable and versatile. These proprietary processes enable us to manufacture and deliver high quality, custom, made-to-order products More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 6,000,000 Positive High 59.61%

Offering Team

  • Legal counsel
  • DLA Piper LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 24 Jun, 2021

Offer 25 Jun, 2021

Look Ahead

Lock Up Expiry Dec 25, 2021

IPO Terms

Offer Price $16.00
Offer Size 6M

Market Sentiments

Stock Price